We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

December 14, 2018

Best of Digital Health 2018

Commentary
Maeve Lyons
&

2018 has been an eventful year in the health tech world - we saw new partnerships and relationships develop, we saw public bodies make their moves in keeping with the evolving digital health landscape, we saw some big fat acquisitions, mergers and entrants, and some not-so-newsworthy failures. As the year draws to a close, we are coming to terms with a number of things: tech companies will make their way into healthcare delivery, CMS will play a vital role in gluing new health plans and traditional players, AI will start showing its impact beyond being cool, patient or human centricity is the most important feature we are seeking, everybody is talking about digital therapeutics. As a community of Pharma, Tech, VC, Provider and Payer groups, we saw them all become more cognizant of the importance of technology in their roles, for the organizations, and for healthcare more broadly.

The best of digital health 2018 drew factors from trending topics, community interest and positive feedback where the content provided insights that benefited our readers in their relevant fields.

4. An Insider’s Guide for Navigating the European Digital Health Investment Landscape

This blog and report was a collaborative effort between HealthXL, Imperial College Health Partners and the EIT Health Investor Network. It was an opportunity to shed a light on digital health investment activity in Europe and how it compares to that of the US that tends to be more in the news for all the moolah it spends on healthcare.

The report looks at the most notable investments and partnerships in Europe and what can we learn from them. It also outlines what elements of policy and regulation in Europe support and impede scaling of new and novel healthcare approaches. Studying the investments of five key investor groups in Europe, we surmised that 70% of healthcare deals included at least one European investor, biopharma and device series A investments saw record levels with the influx of European investment in new technologies, the UK reaffirmed its venture leadership position, nearly tripling the value and volume of deals compared to the second largest country driving investments, Germany.

The UK and Germany have been home to some of the most significant European digital health movements, setting solid groundwork for those to follow and helping to make the environment increasingly more appealing for global investors and innovators. Is this a case of slow and steady wins the race?

What did we learn from this? Strict data regulation, universal health coverage and a strong enterprise and start-up ecosystem have positioned European healthcare for success.

3. How Pharma Should Use Digital Health To Improve Clinical Trials

Leveraging digital tools can help to overcome challenges associated with traditional clinical trials and greatly enhance research. In this blog, we looked at the opportunity for digital health to help diversify patient populations, to prevent drop-offs and to reduce costs in clinical trials. Using Science37 as an example, we saw how technology can help to overcome physician bias for patient selection and physical barriers to access -  the main reasons why there is so little diversity represented in standard clinical trials. We also explored how continuous remote patient monitoring generates significantly larger volumes of data than in standard trials, increasing the number of data points generated from each patient, and in turn reducing the cost and time taken to conduct the trial. Taking all of our learnings into account, we defined what a robust digitally enables clinical trial looks like: a considered, patient-centric approach, leveraging appropriate digital health tools, and generating actionable, insightful data.

 

What did we learn from this? Although digitized clinical trials are nice to have, and have a plausibly lucid value prop, they are not the norm yet. We hope to see more large scale, site-less, digitally enabled RCTs take off and collect meaningful data.

2. HealthXL Digital Therapeutics Report

There’s no doubt that Digital Therapeutics was the buzzword of 2018. The term came into existence under the premise that mobile software can be effective medical treatments. Investments and changes to regulation have taken place over a relatively short period of time allowing a surge of DTx companies to get their solutions to market. Has a new category of medicines arrived? Have you suddenly seen a surge in re-branding of digital health solutions as digital therapeutics? We certainly have. It takes 17 years and $2.5 billion to develop a market ready drug with no guarantee that it will work. It is no wonder DTx has entered healthcare like the knight in shining armor. Easier to collect data, iterate and refine treatment and evidence efficacy, allowing treatments to change with the needs of the population.

In our report released in December, we addressed key areas to equip our community with the knowledge on the entire DTx space - investment, strategic partnerships, emerging business models, evidence generation, prescription, regulation, reimbursement and end user feedback.

The blog is a teaser for the report which can be purchased online now.


What did we learn from this? We will continue the DTx conversation next year, more robust regulatory moves will be made by the FDA and other bodies, there will be dissemination of information about DTx to physicians and patients, there will be a push for payers to offer these solutions in their portfolio.

1. A Beginners Guide to the Anatomy of Blockchain In Healthcare

The question has been asked time and time again - will blockchain fix healthcare? Digital has afforded new challenges and opportunities in healthcare given existing concerns being the interoperability of medical records and data.  

Gathering of patient data has raised important questions about access, shareability and ownership of the health related information. While there is no right answer or strategy in place to address the above points there is a multitude of companies exploring the space and we’ve highlighted them in our blog.

The success of this blog comes as no surprise as it’s representative of an industry that is still figuring out the best practices to apply to the fragile topic which is our privacy and our health. We wanted to correct any misconceptions about what blockchain provides,where your data goes, it’s reliability and tried to demystify it because it is not yet so well understood, it has not yet proven to be the panacea for our health data woes.

Making inroads on blockchain now with smaller projects that do not involve patient data can help prepare healthcare organizations for larger blockchain tasks while adding value in the short time by cutting costs and streamlining data. Blockchain could help solve some of the industry’s most pressing compliance, interoperability, and data security issues, as well as enable new patient-centric business models. But unlocking blockchain’s potential for healthcare will be a slow process, and change is unlikely to come fast.

What did we learn from this? Blockchain is going to remain cool terminology for people to talk about on social media, but as healthcare people, we are only still exploring the possibilities.

It has been an exciting year to be at the forefront of educating, exchanging and collaborating in digital health. We will embrace 2019 equipped with data, the right DNA, and the best community.



We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.